Unum Therapeutics Appoints Jörn Aldag, an Acclaimed Biotechnology Veteran and Gene Therapy Pioneer, to its Board of Directors

February 09, 2016 08:00 AM Eastern Standard Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, today announced the appointment of Jörn Aldag to its Board of Directors. Mr. Aldag brings over two decades of experience leading innovative biotech companies.

"As cellular immunotherapies emerge as one of the most promising approaches in oncology, Unum's leadership team and ACTR technology position the company for success"

Tweet this
"Jörn is one of the true pioneers in building companies that bring novel and potentially curative therapies to patients with severe conditions, and we are very excited to have him join our board," said Chuck Wilson, PhD, President & CEO of Unum Therapeutics. "With his experience, I expect Jörn to provide invaluable insights to our team as we continue to build Unum, seek to bring our Antibody-Coupled T-cell Receptor (ACTR) therapy to patients, and work to change the way cancer is treated."

Mr. Aldag currently serves as the Chairman of Molecular Partners AG, Zurich, Switzerland (SWIX:MOLN)—a company developing a new class of small protein therapies called DARPins. Until recently, he was the Chief Executive Officer of the gene therapy company uniQure N.V. (NASDAQ:QURE), the first company to ever receive approval of a gene therapy product from a Western regulatory agency.

"As cellular immunotherapies emerge as one of the most promising approaches in oncology, Unum's leadership team and ACTR technology position the company for success," said Mr. Aldag. "I am looking forward to working with the Board and Unum's management during the next phase of the company's growth."

Before his tenure at uniQure, Mr. Aldag was President and CEO of Evotec AG, a leading company focused on small molecule drug discovery. There he successfully developed a pipeline of CNS programs and drove the acquisitions of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. Mr. Aldag holds business degrees from the European Business School and Harvard Business School.

Unum Therapeutics

Unum uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer. The Company's lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is in Phase 1 clinical testing to assess its safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com. 

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.